SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending as investors eagerly await a "game-changer" partnership announcement, hinted at by management as coming prior to the new year. This potential alliance, especially in the federal and sovereign AI sectors, is fueling strong bullish sentiment for a significant revenue boost and short squeeze, though some in the community express skepticism over its timing and market impact.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending due to a proposed merger with Applied Digital's cloud computing business, aiming to pivot into an AI GPU compute platform named ChronoScale. This potential transformation from a medical device company to an AI infrastructure player is driving market conversation. The community is actively discussing the implications of this shift, with many anticipating a significant re-rating given exposure to AI and a low share float, though some express concerns regarding shareholder dilution.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech (MTEX) is currently trending due to its exceptionally low public float, which is generating significant retail investor interest and speculation for a potential short squeeze. The community is actively discussing the stock's potential for rapid upward movement, with many eyeing key resistance levels and recent strong profitability metrics as drivers, despite some acknowledgment of past revenue trends. This micro-cap's tight share structure and increasing volume are fueling intense conversation around its parabolic breakout potential.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies ($OPEN) is currently trending amidst a polarized community, with recent positive pending home sales data providing a potential tailwind for the real estate sector. Bulls are optimistic about new management's AI-driven strategy and targeted profitability by 2026, viewing current price weakness as a tax-loss selling opportunity for 'smart money'. However, bears remain vocal, dismissing the stock as overvalued with a flawed business model, predicting further declines as the debate over its long-term viability intensifies.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is witnessing intense investor interest driven by recent preliminary data suggesting a significant reduction in breast cancer recurrence rates and the extension of insider share lock-ups through September 2026. This robust insider commitment, coupled with the stock's low float and an exceptionally high cost to borrow, has sparked widespread community discussion about a potential short squeeze. Many participants are expressing strong confidence in management and the treatment's transformative potential, anticipating substantial long-term value or an acquisition.

Intelligent Living Application Group, Inc. engages in the manufacturing and selling of mechanical locksets. It focuses in producing mechanical locksets including locksets for outdoors such as main entrances and gates and indoors. The firm offers a range of original design manufacturer door locksets to various customer segments with classic to contemporary looks, functions and colors. The company was founded by Po Wang Hui in 1981 and is headquartered in Hong Kong.

Intelligent Living Application Group Inc

Intelligent Living Application Group (ILAG) is attracting significant attention, notably after a recent reverse stock split and regaining Nasdaq compliance, alongside reported increases in revenue and gross profit. The community is actively discussing the stock's reduced share float and a new equity incentive for its CEO, with many anticipating the potential for parabolic moves similar to other high-flying 'Hong Kong' and 'Chinese' stocks.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is navigating extreme volatility due to recent margin requirement increases on silver futures, leading to a notable price pullback. Despite this, community sentiment is sharply divided, with bulls viewing the dip as a buying opportunity fueled by strong industrial demand and impending Chinese export restrictions. Bears, however, warn of a potential market top and highlight the ongoing tension between paper market movements and underlying physical supply dynamics.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is trending as its CEOs public comments on the Federal Reserves independence drive market discussion, while investors anticipate new long-term financial targets to be unveiled at its upcoming Investor Day. The community is also actively weighing how potential Fed rate cuts, alongside the bank's strategic AI investments and expanding crypto allocation for clients, could shape its future growth and competitive standing.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye Global is at the center of a divided community discussion following recent earnings, which, despite meeting expectations, did little to stem the stock's ongoing decline. Investors are actively debating the long-term potential of its autonomous driving technology and partnerships, such as with lidar provider Innoviz, against a backdrop of market skepticism and intense competition. While many lament the stock's performance, a counter-narrative sees the current levels as an opportune entry point given the company's strong fundamentals and future prospects in ADAS and robotaxis.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

AMGN is trending as the community eagerly awaits updates on its MariTide weight-loss drug, with intense discussions around its efficacy, tolerability, and competitive positioning against rival therapies. The company's recent strong earnings and positive trial results for its Repatha cholesterol treatment, coupled with strategic direct-to-consumer pricing initiatives, are also driving significant investor interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$EXOZ I was having a further think over eXoZymes&#39; R&amp;D process and after some research, I think this is what the company may do... 
 
PART ONE 
1. Define the target compound&#39;s chemical formula and structure 
 
2. Using Retrobiosynthesis, they then work backwards from the target to the starting feedstock (sugar) to map possible: 
- a: Enzyme cascades using both external enzyme databases and their own internal database and AI computational design tools. With time, eXoZymes&#39; internal database will expand with lots of Exozyme data, so this stage will get faster 
- b: The supportive frameworks and systems, including the enzymes required to recycle cofactors 
 
3. They then use high-performance Computational Protein Design to assess the possible production Systems&#39; performance data (maximum yield etc) as well as broadly model the economic feasibility of production 
 
PART TWO 
4: Grow the required enzymes and Exozymes in cells and harvest them 
 
continued in comments...

StockTwits Web

eXoZymes Inc.

 I was having a further think over eXoZymes' R&D process and after some research, I think this is what the company may do... 
 
PART ONE 
1. Define the target compound's chemical formula and structure 
 
2. Using Retrobiosynthesis, they then work backwards from the target to the starting feedstock (sugar) to map possible: 
- a: Enzyme cascades using both external enzyme databases and their own internal database and AI computational design tools. With time, eXoZymes' internal database will expand with lots of Exozyme data, so this stage will get faster 
- b: The supportive frameworks and systems, including the enzymes required to recycle cofactors 
 
3. They then use high-performance Computational Protein Design to assess the possible production Systems' performance data (maximum yield etc) as well as broadly model the economic feasibility of production 
 
PART TWO 
4: Grow the required enzymes and Exozymes in cells and harvest them 
 
continued in comments...

James

5: Then they test the Systems in the lab using their BioClick technology (high-throughput screening and AI), which recognises beneficial patterns in the millions of data points captured. 
 
6: The AI model suggests possible engineering optimisations to the enzymes, which could improve the system&#39;s performance. The team may also refine certain parameters (pH, Cofactor levels etc), designing in a new Exozyme System 
 
7: With an optimised Exozyme System, they then test it again in the lab with the results feeding back into their AI model 
 
PART THREE 
8: Once they have determined the final optimised Exozyme System for that target compound, they then run it a few times to validate and replicate the results. Here they may choose to announce the results to the market (eg. 4 grams of NCT) 
 
9: Next, they scale the final Exozyme System to a pilot plant and make adjustments and refinements where necessary and update the economic model

5: Then they test the Systems in the lab using their BioClick technology (high-throughput screening and AI), which recognises beneficial patterns in the millions of data points captured. 
 
6: The AI model suggests possible engineering optimisations to the enzymes, which could improve the system's performance. The team may also refine certain parameters (pH, Cofactor levels etc), designing in a new Exozyme System 
 
7: With an optimised Exozyme System, they then test it again in the lab with the results feeding back into their AI model 
 
PART THREE 
8: Once they have determined the final optimised Exozyme System for that target compound, they then run it a few times to validate and replicate the results. Here they may choose to announce the results to the market (eg. 4 grams of NCT) 
 
9: Next, they scale the final Exozyme System to a pilot plant and make adjustments and refinements where necessary and update the economic model

PART FOUR 
10: Again, once they have validated their Exozyme System at Pilot Plant scale, they publish results and transfer the tech to a CMO 
 
Tyler Korman, CSO, speaks directly about Step 2a in the following video: 
https://www.youtube.com/watch?v=sGtr189FEV0

How is eXoZymes (Nasdaq: EXOZ) uniquely positioned to take advantage of AI? In the words of VP of Research, Tyler Korman, PhD: "The ability to engineer enzymes, it's complex and it can take a lot of time. So, AI is a fundamental tool that we use to really speed up timelines.

YouTube

How is eXoZymes (Nasdaq: EXOZ) uniquely positioned to take advantage of AI? I

PART FOUR 
10: Again, once they have validated their Exozyme System at Pilot Plant scale, they publish results and transfer the tech to a CMO 
 
Tyler Korman, CSO, speaks directly about Step 2a in the following video: 
